Physician profile
Michael Anthony Fallucco
NPI 1851594436
$36,692.18
in general payments reported to CMS, 2019-2025
35 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 84% of Plastic Surgery Within The Head and Neck providers received nationally (typical 2025 total: $300).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $9,601 · 2021: $403 · 2022: $23K · 2023: $1,222 · 2024: $524 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,850 · Travel and Lodging: $147 · Grant: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,849.54 |
| Travel and Lodging | $147.16 |
| Grant | $100.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Surgical Innovation Associates, INC. | $22,045.84 | 2022 | |
| Baxter Healthcare | $9,440.46 | 2019-2021 | |
| Musculoskeletal Transplant Foundation INC. | $1,562.39 | 2021-2025 | |
| Mentor Worldwide LLC | $981.49 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Allergan, INC. | $524.53 | 2019-2022 | |
| Tela Bio, INC. | $451.38 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Abbvie INC. | $437.44 | 2023-2025 | |
| Sientra, INC. | $148.82 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $109.89 | 2023-2025 | Gore Enform Preperitoneal Biomaterial |
| Access Pro Medical, LLC | $105.42 | 2023 | Matriderm |
| Motiva USA, LLC | $103.85 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $61.78 | 2020-2024 | Exparel, Zilretta, Iovera |
| Smith+Nephew, INC. | $60.72 | 2019-2025 | Collagenase Santyl |
| Ethicon US, LLC | $58.83 | 2025 | Dermabond Prineo, Monocryl, Vistaseal |
| Avita Medical Americas, LLC | $54.84 | 2025 | Permeaderm, Recell, Cohealyx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $53.51 | 2025 | |
| Axogen | $51.98 | 2025 | |
| Royal Biologics, INC. | $48.50 | 2025 | |
| Davol INC. | $41.65 | 2025 | Phasix Mesh |
| Acera Surgical, INC. | $40.81 | 2022-2025 | Restrata Wound Matrix |
| Kerecis Limited | $38.71 | 2020-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Innovation Technologies INC | $27.86 | 2020-2025 | Irrisept |
| Galderma Laboratories, L.P. | $27.12 | 2019-2020 | |
| Medela LLC | $26.23 | 2020 | |
| Solventum Corporation | $23.40 | 2025 | Activ.A.C., Prevena, V.A.C. Veraflo |
| Boston Scientific Corporation | $22.38 | 2025 | General - Pain Management |
| Organogenesis INC. | $22.03 | 2024 | Cygnus Dual |
| Aroa Biosurgery Incorporated | $21.64 | 2024 | |
| Kci USA, INC. | $19.59 | 2019 | |
| Pacira Therapeutics, INC. | $18.75 | 2019 | |
| Zimmer Biomet Holdings, INC. | $17.78 | 2019 | |
| Stryker Corporation | $16.28 | 2021 | |
| Solta Medical, A Division of Bausch Health US, LLC | $13.77 | 2020 | |
| Integra Lifesciences Corporation | $12.51 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fallucco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.